BIOMAT Database Logo BIOMAT Database Logo

Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. 1979

M I Whitehead, and R J King, and J McQueen, and S Campbell

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D002979 Climacteric Physiologic period, characterized by endocrine, somatic, and psychic changes with the termination of ovarian function in the female. It may also accompany the normal diminution of sexual activity in the male. Change of Life,Climacterics,Life Change,Life Changes
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria
D004960 Estradiol Dehydrogenases Enzymes that catalyze the oxidation of estradiol at the 17-hydroxyl group in the presence of NAD+ or NADP+ to yield estrone and NADH or NADPH. The 17-hydroxyl group can be in the alpha- or beta-configuration. EC 1.1.1.62 17 beta-Estradiol Dehydrogenase,Estradiol 17 alpha-Dehydrogenase,Estradiol 17 beta-Dehydrogenase,Estradiol Dehydrogenase,17 alpha-Dehydrogenase, Estradiol,17 beta Estradiol Dehydrogenase,17 beta-Dehydrogenase, Estradiol,Dehydrogenase, 17 beta-Estradiol,Dehydrogenase, Estradiol,Dehydrogenases, Estradiol,Estradiol 17 alpha Dehydrogenase,Estradiol 17 beta Dehydrogenase
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D005260 Female Females

Related Publications

M I Whitehead, and R J King, and J McQueen, and S Campbell
Vasoconstrictory thromboxane A2 and vasodilatory prostacyclin in climacteric women: effect of oestrogen-progestogen therapy.
March 1984, Maturitas,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy.
September 1979, Lancet (London, England),
M I Whitehead, and R J King, and J McQueen, and S Campbell
Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms.
March 1989, Maturitas,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Blood pressure during oestrogen/progestogen substitution therapy in healthy post-menopausal women.
March 1988, Maturitas,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Endometrial effects of a continuous percutaneous oestrogen/low dose oral progestogen regimen for climacteric complaints.
April 1987, Maturitas,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Endometrial carcinoma after cyclical oestrogen-progestogen therapy for Turner's syndrome.
May 1975, British journal of obstetrics and gynaecology,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Endometrial factors under treatment with oestrogen and oestrogen/progestogen combinations.
January 1978, Postgraduate medical journal,
M I Whitehead, and R J King, and J McQueen, and S Campbell
CLIMACTERIC and oestrogen therapy.
January 1953, British medical journal,
M I Whitehead, and R J King, and J McQueen, and S Campbell
Endometrial histology and parentereal estrogen-progestogen administration.
January 1969, Fertility and sterility,
M I Whitehead, and R J King, and J McQueen, and S Campbell
The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
November 2000, BJOG : an international journal of obstetrics and gynaecology,
Copied contents to your clipboard!